By Bruce Krasting
Abbott Lab’s cholesterol drug, Niaspan, got a patent way back in 1997. The folks at Abbott have been selling a ton of this crap ever since. It is in the Top 50 of all drug sales. I don’t have the total cumulative sales, but in 2009 global revenue came to $717,000,000, in 2010 it was more than $900mm. Over the life of the drug, total sales are in the tens of billions. The stuff is worthless. It might even be bad for you.
The National Institute of Health did a five-year study. The conclusion:
“The lack of effect on cardiovascular events is unexpected and a striking contrast to the results of previous trials and observational studies,” said Jeffrey Probstfield, M.D.